Ironwood Pharmaceuticals (IRWD) EBIAT: 2010-2025
Historic EBIAT for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $40.1 million.
- Ironwood Pharmaceuticals' EBIAT rose 999.29% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.5 million, marking a year-over-year increase of 1014.74%. This contributed to the annual value of $880,000 for FY2024, which is 100.09% up from last year.
- As of Q3 2025, Ironwood Pharmaceuticals' EBIAT stood at $40.1 million, which was up 69.84% from $23.6 million recorded in Q2 2025.
- In the past 5 years, Ironwood Pharmaceuticals' EBIAT ranged from a high of $391.3 million in Q2 2021 and a low of -$1.1 billion during Q2 2023.
- Its 3-year average for EBIAT is -$91.2 million, with a median of $2.3 million in 2024.
- As far as peak fluctuations go, Ironwood Pharmaceuticals' EBIAT slumped by 3,038.18% in 2023, and later skyrocketed by 2,844.07% in 2025.
- Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' EBIAT stood at $41.4 million in 2021, then climbed by 18.11% to $48.9 million in 2022, then crashed by 103.57% to -$1.7 million in 2023, then soared by 229.28% to $2.3 million in 2024, then surged by 999.29% to $40.1 million in 2025.
- Its last three reported values are $40.1 million in Q3 2025, $23.6 million for Q2 2025, and -$37.4 million during Q1 2025.